Navigation Links
Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
Date:1/15/2008

esults in hyporesponsiveness, or tolerance, to antigens. In a preclinical study in a primate model, administration of TRX1 during the development of a primary immune response to a foreign protein, or antigen, resulted in longstanding and specific tolerance to that antigen. This type of suppression of the immune system may have therapeutic benefit in treating autoimmune diseases that occur when the human immune system mistakenly identifies the components of the human body as foreign.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of patients with immune- mediated diseases. In addition to the development of TRX1, Tolerx is currently developing otelixizumab, an anti-CD3 MAb, in type 1 diabetes with its collaboration partner, GlaxoSmithKline. Tolerx is also engaged in preclinical development of new MAb product candidates that engage the body's immune system and further promote and enhance immune responses. This type of therapy is being researched for the treatment of cancer and chronic viral diseases.

Safe Harbor Statement

This press release contains certain statements that are preceded by, followed by, or that include the words "if," "will receive," "is expected to," "may have" or similar expressions or the negation thereof. Such statements, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements regarding Genentech's activities with respect to further development of TRX1, the potential value of payments that may be received by Tolerx pursuant to the agreement with Genentech, and the anticipated progress and development of TRX1 are all forward-looking statements. Such forward- looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, perf
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
2. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
3. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
4. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
5. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
6. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
7. Medarex to Receive Milestone Payment from Amgen
8. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
9. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
10. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
11. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... On Aug. 20, at its annual meeting in ... voted on and approved a delegate resolution opposing the ... Cannabis Corp., a leading Canadian licensed producer of medicinal ... The CMA is quite right to point out that ... material, including medicinal cannabis. While some patients, particularly those ...
(Date:8/22/2014)... -- MC Medical, a subsidiary of Mitsubishi Corporation (MCM), and ... medical device company, have formally agreed to an ... system in Japan . It is anticipated ... Japan in the latter half of 2015. ... portfolio in endoscopic surgery market in Japan ...
(Date:8/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The particulate ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2
... September 9, 2011 The Board of the ... today it agreed to ratify the proposal of the US ... package, designed with the help of EFCG and US industry ... User Fees Act (GDUFA). GDUFA requires the FDA ...
... Advanced Wound Management division of Smith & Nephew (LSE: SN; ... studies on a range of products and therapies from their ... RENASYS* wound care portfolio. The data demonstrate advanced healing strategies ... products. Results of the studies are being presented at the ...
Cached Medicine Technology:European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 2Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 3Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 4
(Date:8/22/2014)... Worth, FL (PRWEB) August 22, 2014 Millennium ... of marijuana, resulting in a high level of drug use ... all ages fight against drug addiction and work to minimize ... highest levels of alcohol and drug addiction in history. According ... 2012, an estimated 23.9 million Americans aged 12 or older—or ...
(Date:8/22/2014)... Norton HealthDay Reporter ... number of Americans on work disability chronically use powerful ... found that between 2007 and 2011, about 44 percent ... prescribed narcotic painkillers each year. And the percentage using ... to 23 percent in 2011. Experts said ...
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... August 22, 2014 Natural Clear Vision ... to restore his own vision from legally blind to perfect ... an investigative review. , “There is a huge portion ... for everyday function, and most people just think that’s the ... eye surgery that can be pretty risky at times,” reports ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced non-small ... progression free survival (PFS) in epidermal growth factor ... treated Asian patients. Also, BIM deletion independently predicts ... The BIM protein can activate the programmed cell ... cells. BIM deletion has been detected in 12.8% ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2
... Racing may be a sport where the,drivers are ... to be as intense as any professional athlete. Hitting ... mentally tough, as well,physically fit, so many look to ... See video from General Motors (NYSE: GM ...
... OSTE ), a global leader in OsteoBiologic ... today that Sam Owusu-Akyaw,Osteotech,s President and Chief Executive ... Technologies Conference in New York.,Mr. Owusu-Akyaw is scheduled ... September 11, 2007. Osteotech, Inc., headquartered in ...
... A new study shows the number of drug-therapy related ... Drug Administration (FDA) nearly tripled between 1998 and 2005. ... Medicine and colleagues reviewed serious and fatal drug events ... consumers, health professionals and drug manufacturers, and found that ...
... disease, researchers say , , MONDAY, Sept. 10 (HealthDay News) -- ... study suggests. , "The intake of usual doses of ... death," said lead researcher Dr. Philippe Autier, from the International ... new finding, published in the Sept. 10 issue of the ...
... the Association for Assessment and Accreditation of Laboratory ... standard for animal care facilities, AAALAC accreditation is ... the humane care and use of animals in ... involves a comprehensive review by AAALAC evaluators, who ...
... Plan Cost Advisor helps consumers determine out-of-pocket health care ... Blue Shield has,introduced a new tool to help consumers ... their needs. The Plan Cost Advisor is available,to consumers ... plan is often intimidating to consumers," said Kim,Bellard, Vice ...
Cached Medicine News:Health News:Study shows adverse drug events reported to the FDA have significantly increased 2Health News:Vitamin D Supplements May Lengthen Life 2Health News:UCSF animal care facility receives top accreditation 2Health News:Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers 2
... Cauteries provide a broad selection of ... wide variety of ophthalmic procedures. Each ... complete with a safety cap to ... position when not in use, and ...
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
... visual acuity system allows you access to ... II. The system includes 10 different optotypes, ... and animated characters. Random character sequencing eliminates ... letter, single line and multiple line selection ...
... Light Probes provide the surgeon with an ... interface to be easily visualized through the ... effect and light scatter technique, the surgeon ... deposits, flap edge folds, corneal flap striae ...
Medicine Products: